Prognostic Value of Soluble Suppression of Tumorigenicity 2 in Chronic Kidney Disease Patients: A Meta-Analysis

Table 4

Subgroup analysis for the predictive value of sST2 on total CVD events.

Subgroups	Total CVD events
		HR (95% CI)	value	Heterogeneity; (%),
Overall	9	1.88 (1.26-2.80)	0.002	89.5%, ≤0.001
Treatment
Dialysis	4	3.43 (1.43-8.24)	0.006	87.8%, ≤0.001
Predialysis	3	1.00 (1.00-1.00)	0.009	0%, 0.441
Txp	2	1.31 (0.94-1.82)	0.112	6.1%, 0.302
Continent
Europe and America	6	1.23 (0.96-1.59)	0.107	70.3%, 0.005
Asia	3	4.64 (1.94-11.10)	0.001	72.8%, 0.025
DM proportion
<Median percentage	4	1.38 (0.93-2.06)	0.112	74.5%, 0.008
≥Median percentage	4	2.30 (1.02-5.21)	0.046	91.5%, ≤0.001
Sample size
<400	6	1.57 (1.06-2.33)	0.023	72.7%, 0.003
≥400	3	2.30 (0.82-6.44)	0.112	94.2%, ≤0.001

CVD: cardiovascular disease; : number of studies; HR: hazard ratio; CI: confidence interval; Txp: transplant patients; DM: diabetes mellitus.